Drug Adefovir (Preveon) Abacavir (1592-U89) Amprenavir (Agenerase; 141W94) Source Gilead 800-GILEAD-5 Glaxo-Wellcome 800-501-4672 Vertex; Glaxo-Wellcome 800-248-9757 Class Nucleotide RT Inhibitor Nucleotide RT Inhibitor Protease Inhibitor Usual Dose 60 mg po qd or 120 mg po qd + L-carnitine 500 mg po qd 300 mg po bid 1200 mg po bid Side Effects (major) Proximal renal tubular dysfunction, nausea, elevated LFTs Hypersensitivity:2–5% usually in first 4 weeks (fever, nausea, vomiting, morbilliform rash) Do not re-challenge Nausea, diarrhea, rash, headache Comments Activity vs. HBV, CMV, HSV Good CNS penetration; non CY450-mediated metabolism Unique resistance profile; clinical significance unknown Enrollment Criteria Failure or intolerance with current therapy; absence of clinically significant renal dysfunction and no concurrent use of nephrotoxic drugs Failure or intolerance with current therapy. Online Trusted Pharmacy Failure or intolerance with current therapy